A review of the clinical efficacy and tolerability of almotriptan in acute migraine

Bibliography

• GOADSBY PJ, LIPTON RB, FERRARI MD: Migraine-currentunderstanding and treatment. N Engl. Med. (2002) 346:257–270.
   PubMed Web of Science ®Google Scholar
• LIPTON RB, STEWART WE DIAMOND S, DIAMOND ML, REED M: Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache (2001) 41:646–657.
   PubMed Web of Science ®Google Scholar
• LIPTON RB, STEWART WF: Acute migraine therapy: do doctors understand what patients with migraine want from therapy? Headache (1999) 39\(Suppl. 2):520–526.
   Google Scholar
• GALLAGHER RIVI, KUNKEL R: Migrainemedication attributes important for patient compliance: concerns about side effects may delay treatment. Headache (2003) 43:36–44.
   PubMed Web of Science ®Google Scholar
• •Despite the disabling nature of migraine attacks, this survey demonstrated remarkable non-compliance amongst migraine sufferers because of the fear of adverse side effects associated with the use of acute migraine medications.
   Google Scholar
• FERRARI MD, GOADSBY PJ, ROON KI, LIPTON RB: Triptans (serotonin, 5-HTIB/ID agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials. Cephalalgia (2002) 22:633–658.
   PubMed Web of Science ®Google Scholar
• BOU J, DOMENECH T, PUIG J et al.: Pharmacological characterization of almotriptan: an indolic 5-HT receptor agonist for the treatment of migraine. Eur: Pharmacy] (2000) 410:33–41.
   PubMed Web of Science ®Google Scholar
• BOU J, GRAS J, CORTIJO J, MORCILLO EJ, LLENAS J, PALACIOS JM: Vascular effects of the new antimigraine agent almotriptan on human cranial and peripheral arteries.Cephalalgia (2001) 21:804–812.
   PubMed Web of Science ®Google Scholar
• JANSAT JM, COSTA J, SALVA P,FERNANDEZ FJ, MARTINEZ-TOBED A:Absolute bioavailability, pharmacolkinetics, and urinary excretion of the novel antimigraine agent almotriptan in healthy male volunteers. J. Cl/n. Pharmacy] (2002) 42:1303–1310.
   PubMed Web of Science ®Google Scholar
• CABARROCAS X, WARRINGTON SJ,JANSAT JM, ZAYAS JM, BOYCE M, FERRER P: Pharmacolkinetics and tolerability of oral almotriptan in the elderly. Cephalalgia (1999) 19:363.
   Web of Science ®Google Scholar
• GARCIA E, CABARROCAS X, JANSAT JM: A clinical trial to determine 1162Expert Op/n. Pharmacother. (2003) 4(7)
   Google Scholar
• ••the lack of food interaction on the bioavailability of almotriptan, a new 5HT1sim agonist, in healthy volunteers. Headache (1998) 38:376 (Abstract).
   Google Scholar
• DAHLOF C, TFELT-HANSEN P, MASSIOU H, FAZEKAS A: Dose finding, placebo-controlled study of oral almotriptan in the acute treatment of migraine. Neurology (2001) 57:1811–1817.
   PubMed Web of Science ®Google Scholar
• CABARROCAS X, SALVA M: Pharmacokinetic and metabolic data on almotriptan, a new antimigraine drug. Cephalalgia (1997) 17:421.
   Google Scholar
• SALVA M, JANSAT JM,MARTINEZ-TOBED A, PALACIOS JM: Identification of the human liver enzymes involved in the metabolism of the antimigraine agent almotriptan. Drug Metab.Dispos. (2003) 31:404–411.
   PubMed Web of Science ®Google Scholar
• CABARROCAS X, FERNANDEZ FJ, POPESCU G, JANSAT JM, MOLZ K, FERRER P: The pharmacokinetics and tolerability of almotriptan in renal impairment. Headache (1999):346.
   Google Scholar
• FLEISHAKERJC, HERMAN BD, CAREL BJ, AZIE NE: Interaction between ketoconazole and almotriptan in healthy volunteers. Clin. PhannacoL (2003) 43(4):423–427.
   Google Scholar
• FLEISHAKER JC, RYAN KK, CAREL BJ, AZIE NE: Evaluation of the potential pharmacokinetic interaction between almotriptan and fluoxetine in healthy volunteers. Clin. PhannacoL (2001) 41:217–223.
   Google Scholar
• FLEISHAKERJC, SISSON TA, CAREL BJ,AZIE NE: Pharmacokinetic interaction between verapamil and almotriptan in healthy volunteers. Clin. Phannacol Ther. (2000) 67:498–503.
   PubMed Web of Science ®Google Scholar
• FLEISHAKERJC, SISSON TA, CAREL BJ,AZIE NE: Lack of pharmacokinetic interaction between the antimigraine compound, almotriptan, and propranolol in healthy volunteers. Cephalalgia (2001) 21:61–65.
   PubMed Web of Science ®Google Scholar
• BOYCE M, DUNN K, WARRINGTON S: Hemodynamic and electrocardiographic effects of almotriptan in healthy volunteers. Cardiovasc. Phannacol. (2001) 37:280–289.
   PubMed Web of Science ®Google Scholar
• FLEISHAKERJC, MCENROE JD, AZIE NE, FRANCOM SF, CAREL BJ:Cardiovascular effect of almotriptan in treated hypertensive patients. Clin.Phannacol Ther. (2002) 71:169–175.
   PubMed Web of Science ®Google Scholar
• DODICK DW: Oral almotriptan in thetreatment of migraine: safety and tolerability. Headache (2001) 41:449–455.
   PubMed Web of Science ®Google Scholar
• •Pooled results from three pivotal, randomised, controlled trials of almotriptan demonstrating a superior tolerability profile.
   Google Scholar
• DOWSON AJ, MASSIOU H, LAINEZ JM, CABARROCAS X: Almotriptan is an effective and well-tolerated treatment for migraine pain: results of a randomized, double-blind, placebo-controlled clinical trial. Cephalalgia (2002) 22:453–461.
   PubMed Web of Science ®Google Scholar
• PASCUAL J, FALK RM, PIESSENS F et al.: Consistent efficacy and tolerability of almotriptan in the acute treatment of multiple migraine attacks: results of a large, randomized, double-blind, placebo-controlled study. Cephalalgia (2000) 20:588–596.
   PubMed Web of Science ®Google Scholar
• SPIERINGS EL, GOMEZ-MANCILLA B, GROSZ DE, ROWLAND CR,WHALEY FS, JIRGENS KJ: Oral almotriptan versus oral sumatriptan in the abortive treatment of migraine: a double-blind, randomized, parallel-group, optimum-dose comparison. Arch. Neurol (2001) 58:944–950.
   PubMed Web of Science ®Google Scholar
• DODICK DW: Almotriptan increases sustained pain-free outcomes in acute migraine: results from 3 controlled clinical trials. Headache (2002) 42:21–27.
   PubMed Web of Science ®Google Scholar
• MATHEW N: A long-term open-label study of oral almotriptan 12.5 mg for the treatment of acute migraine attacks. Headache (2002) 42:32–40.
   Google Scholar
• PASCUAL J, FALK R, DOCEKAL R et al: Tolerability and efficacy of almotriptan in the long-term treatment of migraine. Eur. Neurol (2001) 45:206–213.
   PubMed Web of Science ®Google Scholar
• CADY RK, SHEFTELL F, LIPTON RB et al.: Effect of early intervention with sumatriptan on migraine pain: retrospective analyses of data from three clinical trials. Clin. Ther. (2000) 22:1035–1048.
   PubMed Web of Science ®Google Scholar
• CADY RK, LIPTON RB, HALL C, STEWART WE O'QUINN S, GUTTERMAN D: Treatment of mild headache in disabled migraine sufferers:results of the Spectrum Study. Headache (2000) 40:792–797.
   PubMed Web of Science ®Google Scholar
• PASCUAL J, CABARROCAS X: Within-patient early versus delayed treatment of migraine attacks with almotriptan: the sooner the better. Headache (2002) 42:28–31.
   PubMed Web of Science ®Google Scholar
• •Further evidence to support the superior efficacy of triptans in general, and for almotriptan in particular, when used early in the course of a migraine attack during the mild pain phase.
   Google Scholar
• MATHEW NT: Early intervention with almotriptan improves pain-free and sustained pain-free responses in the treatment of acute migraine. Headache (2003) (In Press).
   Google Scholar
• DOWSON A, MASSIOU H, LAINEZ JM, CABARROCAS X: Almotriptan improves response rates when treatment is within 1 hour of migraine onset.Headache (2003) (In Press).
   Google Scholar
• MATHEW NT: Use of rescue medication in trials of almotriptan versus placebo in the treatment of acute migraine. Clin. Ther. (2002) 24:520–529.
   PubMed Web of Science ®Google Scholar
• FERRARI MD, ROON KI, LIPTON RB, GOADSBY PJ: Oral triptans (serotonin 5 HTIBRD agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet (2001) 358: 1668-1675.
   Google Scholar
• ••A meta-analysis of 53 randomised,triptan trials involving 24,000 patients. In the absence of head-to-head trials for each triptan, this large analysis provides a good evidence-base for selecting between oral triptans.
   Google Scholar
• FERRARI MD, GOADSBY PJ, LIPTON RB: The use of multiattribute decision models in evaluating triptan treatment options in migraine. Cephalagia (2003) (In Press).
   Google Scholar